Additional Proxy Soliciting Materials (definitive) (defa14a)
19 Julho 2022 - 6:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
Filed by
the Registrant x
Filed by a
party other than the Registrant ¨
Check the appropriate box:
¨ |
Preliminary Proxy Statement |
¨ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
¨ |
Definitive Proxy Statement |
x |
Definitive Additional Materials |
¨ |
Soliciting Material Under §240.14a-12 |
VYNE THERAPEUTICS INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
x | No fee required |
¨ | Fee paid previously with preliminary materials |
¨ | Fee computed on table in exhibit required by Item 25(b) per
Exchange Act Rules 14a-6(i)(1) and 0-11 |
YOUR VOTE
IS IMPORTANT
PLEASE VOTE
YOUR PROXY TODAY
July 19, 2022
Dear Stockholders,
According to our latest records,
we have not received your voting instructions for the Annual Meeting of Stockholders of VYNE Therapeutics Inc., to be held on August 10,
2022. Your vote is extremely important, no matter how many shares you hold.
For the reasons set forth
in the proxy statement, the Board of Directors recommends that you vote FOR the election of the director nominees named in Proposal
No. 1 of the Proxy Statement; FOR the ratification of the appointment of Baker Tilly US, LLP as the independent registered public
accounting firm, as described in Proposal No. 2 of the Proxy Statement; FOR the approval and adoption of the Reverse Stock Split
Amendment, as described in Proposal No. 3 of the Proxy Statement; and FOR the approval of the adjournment of the Annual Meeting,
if necessary, to solicit additional proxies if there are insufficient votes to adopt Proposal 3, as described in Proposal 4 of the Proxy
Statement.
If you need assistance voting
your shares, please call D.F. King & Co., Inc. toll free at (800) 901-0068. On behalf of your Board of Directors, thank you for your
cooperation and continued support.
|
Sincerely, |
|
|
|
|
|
David Domzalski |
|
President and Chief Executive Officer |
Three
easy ways to vote
Menlo Therapeutics (NASDAQ:MNLO)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Menlo Therapeutics (NASDAQ:MNLO)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
Notícias em tempo-real sobre Menlo Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Vyne Therapeutics Inc.